References

1. SALOME™  HEAVY MENSTRUAL BLEEEDING professional information.
2. Naafe M, Kariman N, Keshavarz Z, et al. The effect of Hydroalcoholic Extracts of Capsells Bursa-Pastoris on Heavy Menstrual Bleeding: A Randomized Clinical Trial. Journal of Alternative and Complementary Medicine March 2019, 1-7. DOI: 10.1089/acm.2017.0267
3. Medscape. Menorrhagia. [Online] [20 Dec 2018] Accessed 11 Feb 2021. Available from: https://emedicine.medscape.com/article/255540-print

 Complementary Medicine: D33.6 Western Herbal Medicine.

SALOME™  HEAVY MENSTRUAL BLEEDING. Each capsule contains Shepherd’s Purse Dry Extract 2% Polyphenols [Capsella bursa-pastoris (L) Medikus] 400 mg

This unregistered medicine has not been evaluated by the SAPHRA for its quality, safety or intended use.

3Sixty Biopharmaceuticals (Pty) Ltd, Registration No. 2018/432238/07. 7 West Street, Houghton, Johannesburg, 2198.
Tel: +27 010 593 4632. www.3sixtybiopharma.co.za

1. Osayande AS, Mehulic S. Diagnosis and Initial Management of Dysmenorrhoea. Am Fam Physician. 2014;89(5):341-346.
2. Jenabi E, Fereidoony B. Effect of Achillea Millefolium on Relief of Primary Dysmenorrhoea: A Double-Blind Randomized Clinical Trial. Journal of pediatric and adolescent gynaecology. 2015; 28: 402-404
3. Radfar S, Shahoie R, Noori B, et al. Comparative Study on the Effect of Matricaria chamomile and Achillea Millefolium Capsules on Primary Dysmenorrhoea Intensity of Dormitory Students of Kurdistan University of Medical Sciences, 2018. Journal of Pharmaceutical Research International. 2018;25(3): 1-7
4. SALOME MENSTRUAL PAIN professional information.

Complementary Medicine: D33.6 Western Herbal Medicine.
SALOME™  MENSTRUAL PAIN. Each capsule contains Yarrow Dry extract Ratio 4:1 [Achillea millefolium L.] 250 mg.
This unregistered medicine has not been evaluated by SAHPRA for its quality, safety or intended use.

3Sixty Biomedicine (Pty) Ltd, 

1. SALOME™  Polycos PI/PIL.
2. Pizzo A, Laganà AS, Barbaro L. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol, 2014; 30(3):205–208.
3. International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018. Copyright Monash University, Melbourne Australia 2018. Available from: monash.edu/medicine/sphpm/mchri/pcos.
4. Formuso C, Stracquadanio M, Ciotta L. Myo-Inositol vs D-Chiro-Inositol in PCOS Treatment. Minerva Ginecol. 2015;67(4):321-5.
5. Nestler JE, Jakubowicz DJ, Reamer P et al. Ovulatory and Metabolic Effects of D-Chiro-Inositol in the Polycystic Ovary Syndrome. N Engl J Med. 1999;340:1314-1320.
6. Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera M. A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Over-weight Women. International Journal of Endocrinology, Volume 2016, Article ID 3204083, 5 pages http://dx.doi.org/10.1155/2016/3204083
7. La Marca A, Grisendi V, Dondi G, et al. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol, 2015;31(1):52–56.
8. Dupont J, Scaramuzzi RJ. Insulin signalling and glucose transport in the ovary and ovarian function during the ovarian cycle. Biochem. J. 2016;473, 1483–1501.
9. Menachini D, Facchinetti F. Myoinositol: mechanisms of action and role in the treatment of metabolic diseases, infertility and polycystic ovary syndrome. Nutrafoods. 2017;16:147-151. DOI 10.17470/NF-017-1008-3
10. Cheang KI, Baillargeon J-P, Essah PA, Insulin-Stimulated Release of D-Chiro-Inositol-Containing Inositolphosphoglycan Mediator Correlates with Insulin Sensitivity in Women with Polycystic Ovary Syndrome. Metabolism. 2008;57(10):1390–1397.
11. Larner J. D-Chiro-Inositol – Its Functional Role in Insulin Action and Its Deficit in Insulin Resistance. Int. Jnl. Experimental Diab. Res., 2002;3:47-60.
12. Iuorno MJ, Jakubowicz DJ, Baillargeon J-P, et al. Effects of D-Chiro-Inositol in Lean Women with the Polycystic Ovary Syndrome. Endocr Pract. 2002;8:417-423.
13. Piomboni P, Focarelli R, Capaldo A, et al. Protein modification as oxidative stress marker in follicular fluid from women with polycystic ovary syndrome: the effect of inositol and metformin. J Assist Reprod Genet. 2014; 31:1269–1276.
14. Melo AS, Ferriani RA, Navarro PA. Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. Clinics. 2015;70(11):765-769.

Complementary Medicine: Health Supplement D34.12 Multiple substance formulation.
SALOME™  POLYCOS. Each capsule contains D-chiro-inositol 600 mg.
This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

3Sixty Biomedicine (Pty) Ltd, Registration No.2019/093151/07, 23 Impala Road Block B, Chislehurston, Sandton, 2196, Gauteng. Tel: +27 11 783 3579. www.3sixtybiopharma.co.za

1. SALOME™  FERTILITY professional information.
2. Benelli E, Del Ghianda S, Di Cosmo C and Tonacchera M. A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women. Int J Endocrinol Volume 2016, Article ID 320408
   http://dx.doi.org/10.1155/2016/3204083
3. International evidence based guideline for the assessment and management of polycystic ovary syndrome 2018. Copyright Monash University, Melbourne Australia 2018. Available from monash.edu/medicine/sphpm/mchri/pcos.
4. Unfer V, Carlomagno G, Dante G & Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol, 2012;1–7 DOI: 10.3109/09513590.2011.650660
5. Formuso C, Stracquadanio M, Ciotta L. Myo-Inositol vs D-Chiro-Inositol in PCOS Treatment. Minerva Ginecol. 2015;67(4):321-5.
6. La Marca A, Grisendi V, Dondi G, et al. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol, 2015;31(1):52–56.
7. Medical News Today. What is polycystic ovary syndrome? [Online] [5 Jan 2018] Accessed 11 Feb 2021. Available from https://www.medicalnewstoday.com/articles/265309.php
8. Healthline. Polycystic Ovary Syndrome (PCOS): Symptoms, Causes, and Treatment [Online] [29 Mar 2019] Accessed 11 Feb 2021. Available from
   https://www.healthline.com/health/polycystic-ovarydisease
9. Marshall JC, Dunaif A. All Women With PCOS Should Be Treated For Insulin Resistance. Fertil Steril. 2012;97.(1):18–22. doi:10.1016/j.fertnstert.2011.11.036.
10. Mendoza N, Diaz-Ropero MP, Aragon M, et al. Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol, 35:8,695-700 DOI: 10.1080/09513590.2019.1576620
11. Pizzo A, Laganà AS, Barbaro L. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol, 2014;30(3):205–208.
12. Piomboni P, Focarelli R, Capaldo A, et al. Protein modification as oxidative stress marker in follicular fluid from women with polycystic ovary syndrome: the effect of inositol and metformin. J Assist Reprod Genet. 2014;31:1269–1276.

Complementary Medicine: Health Supplement D 34.13 Other SALOME™  FERTILITY.
Each capsule contains Myo-inositol 550 mg and D-chiro-inositol 150 mg.
This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

3Sixty Biomedicine (Pty) Ltd, 7 West Street, Houghton, Johannesburg, 2198 Gauteng South Africa

1. Explore Health. Every question you have about CBD – answered. Explore Health 12 December 2019. Available from: https://www.health.com/condition/pain/what-is-cbd
2. Harvard Medical School, Harvard Health Publishing. Cannabidiol (CBD) — what we know and what we don’t. Available from: https://www.health.harvard.edu/blog/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476
3. MJBizDaily South Africa approves continent’s first federal cannabidiol law. MJBizDaily, 24 May 2019. Available from: https://mjbizdaily.com/south-africa-approves-continents-first-federal-cannabidiol-law/
4. Government Gazette, Republic of South Africa, 23 May 2019, Doc number: 42477
5. Eagleston LRM, Kalani NK, Patel RR, Flaten HK, Dunnick CA, Dellavalle RP. Cannabinoids in dermatology: a scoping review. Dermatol Online J. 2018;24(6). Available from https://escholarship.org/uc/item/7pn8c0sb
6. Marks DH, Friedman A. The therapeutic potential of cannabinoids in dermatology. Skin Therapy Lett. 2018 Dec 23(6): Available from https://www.skintherapyletter.com/dermatology/cannabinoids-potential/
7. Mayo clinic. Diseases and conditions. Dermatitis. Symptoms and causes. [Online] 11 July 2019. Available from: https://www.mayoclinic.org/diseases-conditions/dermatitis-eczema/symptoms-causes/syc-20352380
8. Rao J. A physician’s guide to treating acne. Skin Therapy Lett. 2017 Dec 12(3): Available from: https://www.skintherapyletter.com/acne/physicians-guide/
9. Lovell P, Vender RB. Management and Treatment of Pruritus. Skin Therapy Lett. 2007 Feb;12(1): Available from: https://www.skintherapyletter.com/pruritus/management-treatment/
10. Kurian A, Barankin B. Therapeutic Moisturizers in Eczema and Xerosis Management (Pharmacist Edition). Skin Therapy Lett.2010 Dec;5(2): Available from: https://www.skintherapyletter.com/pharmacist-edition/moisturizers-eczema-xerosis-pharm/
11. United States Patent Application Publication: Pharmacological Treatment of Psoriasis. Pub. No.: US 2008/0255224 A1 Oct. 16,2008